{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:57:48Z","timestamp":1753869468693,"version":"3.41.2"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern AIDS Soc"],"published-print":{"date-parts":[[2018,2]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>When darunavir (DRV<\/jats:styled-content>) 800\u00a0mg is boosted with 150\u00a0mg cobicistat (DRV<\/jats:styled-content>cobi<\/jats:sub>), DRV<\/jats:styled-content> trough concentration (Ctrough<\/jats:sub>) is about 30% lower as compared to 100\u00a0mg ritonavir (DRV<\/jats:styled-content>rtv<\/jats:sub>). DRV<\/jats:styled-content>cobi<\/jats:sub> shows similar virological efficacy as DRV<\/jats:styled-content>rtv<\/jats:sub> when combined with two nucleos(t)ide analogue reverse\u2010transcriptase inhibitors, but it is unknown whether a lower DRV<\/jats:styled-content> Ctrough<\/jats:sub> would undermine the effectiveness of DRV<\/jats:styled-content>cobi<\/jats:sub> when given as monotherapy (mtDRV<\/jats:styled-content>cobi<\/jats:sub>).<\/jats:p><\/jats:sec>Methods<\/jats:title>Prospective observational study on virologically suppressed HIV<\/jats:styled-content>\u2010infected subjects who switched to mtDRV<\/jats:styled-content>cobi<\/jats:sub>. Virological failure was defined as two consecutive HIV<\/jats:styled-content>\u2010RNA<\/jats:styled-content> >200\u00a0copies\/mL<\/jats:styled-content>. Efficacy was evaluated by intention\u2010to\u2010treat (ITT<\/jats:styled-content>) and on\u2010treatment (OT<\/jats:styled-content>) analyses, and compared with data from a previous cohort of subjects on mtDRV<\/jats:styled-content>rtv<\/jats:sub> conducted at our centre. Plasma DRV<\/jats:styled-content> Ctrough<\/jats:sub> was measured using LC<\/jats:styled-content>\u2013MS<\/jats:styled-content>\/MS<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 234 subjects were enrolled. At week 96, the efficacy rates were 67.8% (CI<\/jats:styled-content>95<\/jats:sub>, 61.8 to 73.7) by ITT<\/jats:styled-content> and 86.9% (CI<\/jats:styled-content>95<\/jats:sub>, 78.0 to 87.7) by OT<\/jats:styled-content> analyses. The corresponding rates in our historical DRV<\/jats:styled-content>rtv<\/jats:sub> controls were 67.6% (CI<\/jats:styled-content>95<\/jats:sub>, 60.0 to 75.2) and 83.6% (CI<\/jats:styled-content>95<\/jats:sub>: 77.2 to 90.0). A total of 135 DRV<\/jats:styled-content> determinations were performed in 83 subjects throughout the follow\u2010up period, with a median plasma DRV<\/jats:styled-content> Ctrough<\/jats:sub> of 1305\u00a0ng\/mL<\/jats:styled-content> (range, 150 to 5895) compared with 1710\u00a0ng\/mL<\/jats:styled-content> (range, 200 to 3838) in subjects on monotherapy with DRV<\/jats:styled-content>rtv<\/jats:sub> (p\u00a0<\/jats:italic>=\u00a0<\/jats:italic>0.05).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>DRV<\/jats:styled-content> Ctrough<\/jats:sub> was lower in HIV<\/jats:styled-content>\u2010infected subjects receiving DRV<\/jats:styled-content>cobi<\/jats:sub> than with DRV<\/jats:styled-content>rtv<\/jats:sub>. However, this did not appear to influence the efficacy of DRV<\/jats:styled-content>cobi<\/jats:sub>, when administered as monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.25072","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T09:48:44Z","timestamp":1518428924000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Darunavir\/cobicistat showing similar effectiveness as darunavir\/ritonavir monotherapy despite lower trough concentrations"],"prefix":"10.1002","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-1574","authenticated-orcid":false,"given":"Alicia","family":"Gutierrez\u2010Valencia","sequence":"first","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trujillo\u2010Rodriguez","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Fernandez\u2010Magdaleno","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F","family":"L\u00f3pez\u2010Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas Microbiolog\u00eda y Medicina Preventiva Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0160-x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.290"},{"issue":"11","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1742-6405-11-39","article-title":"Cobicistat\u2010boosted darunavir in HIV\u20101\u2010infected adults: week 48 results of a Phase IIIb, open\u2010label single\u2010arm trial","volume":"1","author":"Tashima K","year":"2014","journal-title":"AIDS Res Ther"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000618"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr504"},{"issue":"8","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkr199","article-title":"96\u00a0week results from the MONET trial: a randomized comparison of darunavir\/ritonavir with versus without nucleoside analogues, for subjects with HIV RNA <50 copies\/mL at baseline","volume":"66","author":"Clumeck N","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148924"},{"issue":"5","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3851\/IMP2722","article-title":"Darunavir minimum plasma concentration and ritonavir\u2010boosted darunavir monotherapy outcome in HIV\u2010infected patients","volume":"19","author":"Gutierrez\u2010Valencia A","year":"2014","journal-title":"Antivir Ther"},{"key":"e_1_2_8_10_1","unstructured":"European AIDS Clinical Society.European Guidelines for treatment of HIV infected adults in Europe. Version 9.2017[cited 2017 Nov 1]. Available fromhttp:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf."},{"key":"e_1_2_8_11_1","unstructured":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida.Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana.2017[cited Oct 1 2017]. Available from:http:\/\/gesida-seimc.org\/wp-content\/uploads\/2017\/02\/gesida-guiasclinicas-2017-TAR.pdf."},{"issue":"4","key":"e_1_2_8_12_1","first-page":"132","article-title":"2017 Update of the drug resistance mutations in HIV\u20101","volume":"24","author":"Wensing AM","year":"2017","journal-title":"Top Antivir Med"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000180077.59159.f4"},{"issue":"6","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jac\/dkn103","article-title":"Long\u2010term (4\u00a0years) efficacy of lopinavir\/ritonavir monotherapy for maintenance of HIV suppression","volume":"61","author":"Pulido F","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir\u2010ritonavir monotherapy versus lopinavir\u2010ritonavir and 2 nucleosides for maintenance therapy of HIV: 96\u2010week analysis","volume":"51","author":"Arribas JR","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq327"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022003"},{"issue":"1","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-10-3","article-title":"Boosted protease inhibitor monotherapy in HIV\u2010infected adults: outputs from a pan\u2010European expert panel meeting","volume":"10","author":"Arribas JR","year":"2013","journal-title":"AIDS Res Ther"},{"issue":"10","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/INF.0b013e318223bc56","article-title":"Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir\u2010boosted protease inhibitor monotherapy","volume":"30","author":"Neth O","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00315-13"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000060"},{"issue":"4","key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.7448\/IAS.17.4.19813","article-title":"Monotherapy with darunavir\/ritonavir is effective and safe in clinical practice","volume":"17","author":"Pasquau J","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12521"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12170"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000521"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000781"},{"issue":"1","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"98.e7","DOI":"10.1016\/j.cmi.2015.09.028","article-title":"Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract","volume":"22","author":"Torres-Cornejo A","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/aid.2014.0299","article-title":"Higher activation in CD4(+) T cells but similar viral control among HIV\/Hepatitis C virus\u2010coinfected patients on a simplification monotherapy","volume":"32","author":"BenMarzouk-Hidalgo OJ","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2016.02.001"},{"issue":"2","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/11598380-000000000-00000","article-title":"Budget impact analysis of switching to darunavir\/ritonavir monotherapy for HIV\u2010infected people in Spain","volume":"10","author":"Pasquau J","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"key":"e_1_2_8_31_1","unstructured":"Rezolsta(darunavir\/cobicistat).Full prescribing information. Janssen-Cilag SpA. European Medicine Agency. [Updated 12\/12\/2014. cited 2014 Dec 30]. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/002819\/WC500178953.pdf"},{"key":"e_1_2_8_32_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.2016. [cited 2016 Jul 16]. Available from:https:\/\/aidsinfo.nih.gov\/contentfiles\/adultandadolescentgl.pdf."},{"issue":"12","key":"e_1_2_8_33_1","first-page":"1","article-title":"HIV\u20101 low\u2010level viremia assessed with 3 commercial real\u2010time PCR assays show high variability","volume":"24","author":"Ruelle J","year":"2012","journal-title":"BMC Infect Dis"},{"key":"e_1_2_8_34_1","unstructured":"U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDS.Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Paediatric Adverse Events Version 2.1.2014[cited 2017 July 16]. Available from:http:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daids_ae_grading_table_v2_nov2014.pdf"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.02.057"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12348"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/11592220-000000000-00000"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0396-x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second\u2010line maintenance treatment for HIV\u20101\u2010infected patients in sub\u2010Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open\u2010label, superiority trial","volume":"4","author":"Ciaffi L","year":"2017","journal-title":"Lancet HIV"},{"key":"e_1_2_8_40_1","unstructured":"PREZISTA\u2122 (Tibotec Inc.)(Darunavir).Full prescribing information. Food and drug administration.2008. [cited 2016 Oct 31]. Available from:http:\/\/accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021976s003s004lbl.pdf."}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjia2.25072","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T04:34:26Z","timestamp":1695616466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/jia2.25072"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25072","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"type":"print","value":"1758-2652"},{"type":"electronic","value":"1758-2652"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25072"}}